Wedbush Reiterates Outperform on Astria Therapeutics, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico reiterates an Outperform rating on Astria Therapeutics (NASDAQ:ATXS) and maintains a $17 price target.
March 05, 2024 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico reaffirmed an Outperform rating on Astria Therapeutics with a $17 price target.
The reiteration of an Outperform rating and a $17 price target by a reputable analyst like Laura Chico suggests a strong vote of confidence in Astria Therapeutics' potential. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in ATXS's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100